Stories from Marburg · Germany

BayonTech is focusing its operations on commercial mRNA manufacturing and Covid-19 vaccine production. The company stated that the transition in Marburg will occur without operational redundancies or layoffs.

BioNTech is laying off 540 employees in Marburg, Germany. The decision follows a period where the company has not been generating profits. The scale of the job losses is described as a impact for the local city. The broadcaster noted that the company's development is no longer as dynamic as in its early stages. This decision affects a portion of the Marburg site's personnel. BioNTech, the German biotechnology company, has announced layoffs impacting approximately 540 employees. The company cited a need for restructuring and cost-saving measures. This decision follows recent financial performance reviews.

BioNTech announced that operations at certain sites will be discontinued by the end of 2027. The group merged with a British consumer goods corporation in 1999. The announcement follows a long history of the entity.

BioNTech plans to reduce production capacity at sites in Idar-Oberstein, Marburg, and Singapore. The head of the IG BCE regional district for Rhineland-Palatinate and Saarland, Strasser, criticized BioNTech's decision to cut production at three sites. Strasser described the move as a "ruthless clear-cutting" that endangers Germany's status as a pharmaceutical hub. He stated that politics and society should not simply accept these developments. The company, which saw high profits from mRNA vaccines during the COVID-19 pandemic, is facing an existential threat from job losses. The IG BCE union has announced its intention to resist the decision. The company is reportedly offering a combination of cash and stock for compensation. BioNTech management announced in Mainz that the company plans to reduce its workforce by up to 1,000 positions.

Companies including CSL Behring and BioNTech are currently cutting hundreds of jobs in Marburg. Research activities are being scaled back despite investments in recent years. The industry is facing pressure to value innovation to maintain economic growth and patient supply.

Dennis Ratke was re-elected as the head of the CDU's labor wing in Marburg, Germany. He reaffirmed his call for strengthening private pension provisions and stated there would be no cuts to the statutory old-age security system.